Hillhouse Capital Management
Cell analysis player Cytek raises $120m Series D
RA Capital and Hillhouse Capital have led a $120 million Series D round for Cytek Biosciences, a California-based cell analysis start-up founded by a former professor at Shanghai's Fudan University.
China cosmetics brand Perfect Diary files for US IPO
Yatsen Holding, the parent company of Chinese cosmetics brand Perfect Diary has filed for a US IPO, potentially delivering a liquidity event for the likes of Hillhouse Capital, ZhenFund and Gaorong Capital.
TCDRS backs trio of Hillhouse funds
Texas County & District Retirement System (TCDRS) has put $200 million towards Hillhouse Capital’s latest Asia fundraising effort, committing to three separate funds.
China's Yuanfudao hits record valuation with $2.2b round
Yuanfudao, a Chinese education start-up that targets the K-12 segment, has raised $2.2 billion in Series G funding at a valuation of $15.5 billion, nearly double the valuation of its previous round, which closed in April.
China's Miniso sees modest trading debut after $608m US IPO
Miniso, a Chinese low-cost retailer backed by Hillhouse Capital and Tencent Holdings, posted a small gain on its US trading debut following a $608 million IPO.
Hillhouse targets $12b for separate buyout, growth funds
China's Hillhouse Capital has split its current fundraising effort into separate buyout and growth strategies – having raised a single pool in the previous vintage – and is seeking $12 billion across the two funds.
Lee's Pharmaceutical spin-out gets $145m Series B
Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO), a subsidiary of Lee’s Pharmaceutical, has raised a $145 million Series B round led by Hillhouse Capital and TPG Asia.
China carpooling player Dida pursues Hong Kong IPO
Dida Chuxing – a Chinese peer-to-peer carpooling business that subsequently expanded into ride-hailing, putting it in direct competition with longstanding market leader Didi Chuxing – has filed for a Hong Kong IPO.
Everest Medicines soars on debut after $451m IPO
Everest Medicines, a Chinese biotech start-up backed by CBC Group, performed strongly in early trading in Hong Kong following a HK$3.5 billion ($451 million) IPO.
Genor Biopharma raises $372m in Hong Kong IPO
China-based Genor Biopharma, which counts Hillhouse Capital, Temasek Holdings and Qiming Venture Partners among its investors, has raised HK$2.88 billion ($372 million) through a Hong Kong IPO.
PE-backed JD Health files for Hong Kong IPO
JD Health, the healthcare unit of Chinese e-commerce giant JD.com, has filed for Hong Kong IPO. The company’s backers include Hillhouse Capital, CPE, CICC Capital, and Baring Private Equity Asia.
Hillhouse leads $418m investment in China's I-Mab
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
Deal focus: China's Xpeng moves into top gear
Investor appetite for Xpeng grew over the course of 2020 as China's electric vehicle industry showed signs of recovery after a difficult 2019. A $500 million Series C extension was soon followed by an IPO filing
Hillhouse founder emphasizes tech transformation opportunities
The most attractive investment opportunities in a post-COVID-19 world involve helping traditional businesses that have been “victims of the creative destruction of technology” play catch-up, according to Lei Zhang, founder and CEO of Hillhouse Capital.
Hillhouse invests $830m in China’s JD Health
Hillhouse Capital has agreed to invest $830 million in JD Health, the healthcare unit of Chinese e-commerce giant JD.com, which will remain the majority shareholder.
Microsoft seeks to acquire TikTok assets from China's ByteDance
Microsoft Corporation wants to continue discussions over the purchase of the US operation of TikTok from PE-backed Chinese technology giant ByteDance amid threats from US President Donald Trump to ban the short video platform.
Chinese real estate platform Beike pursues US IPO
Beike, a Chinese online real estate platform backed by Tencent Holdings, SoftBank Vision Fund and Hillhouse Capital, has filed for US IPO.
Hillhouse invests $1.5b in Chinese EV battery maker
Hillhouse Capital has invested RMB10.6 billion ($1.5 billion) in Chinese electric vehicle (EV) battery manufacturer Contemporary Amperex Technology (CATL). It is part of a RMB19.7 billion capital raise by the Shenzhen-listed company.
China biotech player Antengene raises $97m Series C
Fidelity Investments has led a $97 million Series C round for Chinese hematology and oncology biotech developer Antengene.
Investors commit $500m to China EV maker Xpeng
Chinese electric vehicle (EV) manufacturer Xpeng Motors has closed an extended Series C round of around $500 million from a group that includes Hillhouse Capital and Sequoia Capital China, as well as hedge funds Aspex Management and Coatue Management.
PE-backed Junshi Biosciences shines on Star Market debut
PE-backed Junshi Biosciences has become the first Chinese biotech company to list in Hong Kong and the mainland, following a strong debut on Shanghai's Star Market.
Hillhouse invests $400m in China data center player
Hillhouse Capital has taken a 3.9% interest in US-listed Chinese data center developer GDS Holdings for $400 million.
Chinese instant food brand Baijia raises $28m
Chinese instant food brand Baijia Food has raised RMB200 million ($28 million) in Series B funding led by GL Ventures, the venture capital arm of Hillhouse Capital.
Chinese drug developer Everest secures $310m Series C
Everest Medicines, a China-based biopharmaceutical company, has raised $310 million in Series C funding across two tranches.